Senior Principal Scientist
Bristol Myers Squibb
Princeton
Kun Yang, Ph.D. is a bioanalytical lead at Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis (CPPDB) in Bristol Myers Squibb. At BMS, Kun is developing bioanalytical strategies for various biologics development programs, including cell (CAR-T) & gene therapy (AAV) molecules, antibodies, etc. He is acting as the bioanalytical liaison with clinical, and non-clinical internal cross-functional project teams and external collaborators. He also leads the preparation of regulatory documents including IB, INDs, NDAs, and BLA submission documents and being responsible for responding to Health Authority queries related to bioanalysis.
Risk-Based Bioanalytical Strategy for AAV Gene Therapy for Cardiac Delivery
Tuesday, October 24, 2023
3:45 PM – 4:00 PM ET